The DOI matches its Crossref record; 215 of the 215 references it cites were found in a registry or an index.
Modern Subunit Vaccines: Development, Components, and Research Opportunities
Abstract
Traditional vaccines, based on the administration of killed or attenuated microorganisms, have proven to be among the most effective methods for disease prevention. Safety issues related to administering these complex mixtures, however, prevent their universal application. Through identification of the microbial components responsible for protective immunity, vaccine formulations can be simplified, enabling molecular‐level vaccine characterization, improved safety profiles, prospects to develop new high‐priority vaccines (e.g. for HIV, tuberculosis, and malaria), and the opportunity for extensive vaccine component optimization. This subunit approach, however, comes at the expense of decreased immunity, requiring the addition of immunostimulatory agents (adjuvants). As few adjuvants are currently used in licensed vaccines, adjuvant development represents an exciting area for medicinal chemists to play a role in the future of vaccine development. In addition, immune responses can be further customized though optimization of delivery systems, tuning the size of particulate vaccines, targeting specific cells of the immune system (e.g. dendritic cells), and adding components to aid vaccine efficacy in whole immunized populations (e.g. promiscuous T‐helper epitopes). Herein we review the current state of the art and future direction in subunit vaccine development, with a focus on the described components and their potential to steer the immune response toward a desired response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–215 of 215
Simultaneous Lipidation of a Characterized Peptide Mixture by Chemoselective Ligation
Bourel‐Bonnet, L., Bonnet, D., Malingue, F., Gras‐Masse, H., & Melnyk, O. (2003) · Bioconjugate Chemistry · doi:10.1021/bc0256143 · Cited by 23
Lipidation of intact proteins produces highly immunogenic vaccine candidates
Zeng, W., Eriksson, E. M., Lew, A. M., & Jackson, D. C. (2010) · Molecular Immunology · doi:10.1016/j.molimm.2010.10.003 · Cited by 23
Flagellin produced in plants is a potent adjuvant for oral immunization
Girard, A., Saron, W. A. A., Bergeron-Sandoval, L.-P., Sarhan, F., & Archambault, D. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.06.092 · Cited by 22
Moyle, P. M., Olive, C., Ho, M., Burgess, M. L., Kárpáti, L., Good, M. F., & Tóth, I. (2006) · The Journal of Organic Chemistry · doi:10.1021/jo060960p · Cited by 22
Self-citationImmunization with recombinant protein: conditions for cytotoxic T cell and/or antibody induction
Bachmann, M. F., Hengartner, H., & Zinkernagel, R. M. (1994) · Medical Microbiology and Immunology · doi:10.1007/bf00196682 · Cited by 22
Lipopeptide-Polyoxyethylene Conjugates as Mitogens and Adjuvants
Kleine, B., Rapp, W. E., Wiesmüller, K., Edinger, M., Beck, W., Metzger, J. W., Ataulakhanov, R., Jung, G., & Bessler, W. G. (1994) · Immunobiology · doi:10.1016/s0171-2985(11)80283-4 · Cited by 19
Mitchell, D., Yong, M. C. R., Raju, J., Willemsen, N. M., Black, M., Trent, A. M., Tirrell, M., & Olive, C. (2011) · Human Vaccines · doi:10.4161/hv.7.0.14567 · Cited by 16
Monophosphoryl Lipid A and Synthetic Lipid A Mimetics As TLR4-Based Adjuvants and Immunomodulators
Baldridge, J. R., Myers, K. R., Johnson, D. A., Persing, D. H., Cluff, C. W., & Hershberg, R. M. (2006) · Humana Press eBooks · doi:10.1007/978-1-59259-970-7_12 · Cited by 15
Moyle, P. M., Hari, Y., Huang, N., Olive, C., Good, M. F., & Tóth, I. (2007) · Tetrahedron Letters · doi:10.1016/j.tetlet.2007.05.129 · Cited by 15
Self-citationBultmann, H., Girdaukas, G. G., Kwon, G. S., & Brandt, C. R. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00495-10 · Cited by 10
Ganglioside GM1-binding peptides as adjuvants of antigens inoculated by the intranasal route
Montaner, A. D., Nichilo, A. D., Elı́as, F., Rodríguez, J. M., Fló, J., López, R. A., Zorzópulos, J., & Frank, R. (2005) · Vaccine · doi:10.1016/j.vaccine.2005.10.037 · Cited by 9
Structure-Based Design for High-Hanging Vaccine Fruits
Back, J. W., & Langedijk, J. P. M. (2012) · Advances in immunology · doi:10.1016/b978-0-12-396548-6.00002-0 · Cited by 9
Universal vaccines: shifting to one for many or shooting too high too soon!
Hamad, M. A. (2011) · Apmis · doi:10.1111/j.1600-0463.2011.02776.x · Cited by 7
Possible Applications for Replicating Hiv-1 Vectors
Das, A. T., Jeeninga, R. E., & Berkhout, B. (2010) · HIV Therapy · doi:10.2217/hiv.10.20 · Cited by 7
Structural modification effects on bioactivities of the novel 15-mer peptide adjuvant
Ламан, А. Г., Shepelyakovskaya, A. O., Boziev, K. M., et al. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.07.113 · Cited by 5
Cited by
Multifaceted Roles of Disulfide Bonds. Peptides as Therapeutics
Góngora-Benítez, M., Tulla-Puche, J., & Albericio, F. (2014) · Chemical Reviews · doi:10.1021/cr400031z · Cited by 655
Peptide-based synthetic vaccines
Skwarczynski, M., & Toth, I. (2016) · Chemical Science · doi:10.1039/c5sc03892h · Cited by 596
Self-citationAdvance in peptide-based drug development: delivery platforms, therapeutics and vaccines
Xiao, W., Jiang, W., Chen, Z., Huang, Y., Mao, J., Zheng, W., Hu, Y., & Shi, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02107-5 · Cited by 449
Lamichhane, B., Mawad, A. M. M., Saleh, M., Kelley, W. G., Harrington, P. J., Lovestad, C. W., Amezcua, J., Sarhan, M. M., El Zowalaty, M. E., Ramadan, H., et al. (2024) · Antibiotics · doi:10.3390/antibiotics13010076 · Cited by 353
Designing spatial and temporal control of vaccine responses
Roth, G. A., Picece, V. C. T. M., Ou, B. S., Luo, W., Pulendran, B., & Appel, E. A. (2021) · Nature Reviews Materials · doi:10.1038/s41578-021-00372-2 · Cited by 316
Metadata
- Authors
- Moyle, P. M., & Toth, I.
- Venue
- ChemMedChem
- Publisher
- Wiley
- Published
- 2013-01-11
- Volume
- 8
- Issue
- 3
- Pages
- 360-376
- ISSN
- 1860-7179 (ISSN-L)
- 1860-7187
- OpenAlex
- W1976136842
- Cited by
- 464
- References
- 215
- FWCI
- 11.17
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
